• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study

    2022-04-29 06:30:28RenYiSuSunBinLingQiaoNanShanXuYongWeiRuiWangChangKuJiaLiZhuangTianShenLiMinDingZhiDanXuLaiBangLuoLiBoSunGuangMingLiTaiShiFangNanJiangKunZhangZhaoJieSuZhiHaiPengRenLangTaoJiangQiangHeLinSenYeYangYa

    Ren-Yi Su, Sun-Bin Ling, Qiao-Nan Shan , Xu-Yong Wei , Rui Wang , Chang-Ku Jia , Li Zhuang , Tian Shen , Li-Min Ding , Zhi-Dan Xu , Lai-Bang Luo , Li-Bo Sun, Guang-Ming Li , Tai-Shi Fang , Nan Jiang , Kun Zhang , Zhao-Jie Su , Zhi-Hai Peng , Ren Lang , Tao Jiang , Qiang He , Lin-Sen Ye 0 , Yang Yang 0 , Yu-Ting He , Wen-Zhi Guo , Liu-Gen Lan , Xu-Yong Sun , Dong Chen , Zhi-Shui Chen , Da-Wei Zhou , Shao-Jun Ye , Qi-Fa Ye , Min Tian , Jian-Hua Shi , Bo Wang , Jiang Liu , Qian Lu , Wei Rao , Jin-Zhen Cai , Tao Lv , Jia-Yin Yang , Pu-Sen Wang , Lin Zhong , Jing-Sheng Ma 0 , Qi-Gen Li 0 , Sheng-Dong Wu , Chang-Jiang Lu , Cai-De Lu , Dong-Hua Zhang , Xuan Wang , Zi-Qiang Li , Mu-Jian Teng , Jun-Jie Li , Wen-Tao Jiang , Jian-Hua Li , Quan-Bao Zhang , Ning-Qi Zhu , Zheng-Xin Wang , Kang He , Qiang Xia , Shao-Hua Song , Zhi-Ren Fu , Wei Qiu , Guo-Yue Lv , Rui-Peng Song , Ji-Zhou Wang , Zheng Wang 0 , Jian Zhou 0 , Gang Chen , Ying-Peng Zhao , Li Li , Ze-Min Hu , Qi-Jie Luo , Zhong-Zhou Si , Bin Xie , Xiao-Shun He , Zhi-Yong Guo , Shu-Sen Zheng , , , , Xiao Xu , , ,

    1 Department of Hepatobiliary and Pancreatic Surgery, The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310 0 06, China

    2 NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310 0 03, China

    3 Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou 310022, China

    4 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310 0 03, China

    5 Department of Transplantation, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang 330 0 06, China

    6 Liver Transplantation Center, Beijing You’an Hospital, Capital Medical University, Beijing 10 0 069, China

    7 Department of Hepatic Surgery, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518112, China

    8 Department of General Surgery, Xiang’an Hospital of Xiamen University, Xiamen 3610 0 0, China

    9 Deartment of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 10 0 020, China

    10 Department of Hepatic Surgery and Liver Transplantation Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

    11 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

    12 Department of Liver Transplantation, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530 0 0 0, China

    13 Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    14 Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    15 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

    16 Liver Transplantation Center, Tsinghua Changgung Hospital, Beijing 102218, China

    17 Organ Transplantation Center, Affiliated Hospital of Qingdao University, 59 Haier Road, Laoshan District, Qingdao 266061, China

    18 Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610044, China

    19 Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 20 0 080, China

    20 Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330 0 06, China

    21 Department of Hepatobiliary and Pancreatic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo 315041, China

    22 Liver Transplant Center, General Hospital of Eastern Theater Command, Nanjing 210 0 02, China

    23 Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China

    24 Liver Transplant Department, Tianjin First Center Hospital, Tianjin 300192, China

    25 Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 20 0 040, China

    26 Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

    27 Liver Transplantaiton Center, Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 20 0 025, China

    28 Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun 130021, China

    29 Department of Hepatobiliary Surgery, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of USTC; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230 0 01, China

    30 Department of Liver Surgery & Transplantation, Zhongshan Hospital Fudan University, Shanghai 20 0 032, China

    31 Department of hepato-biliary-pancreatic surgery and liver transplantation center, the First People’ s Hospital of Kunming, Kunming 650 0 0 0, China

    32 Department of Hepatobiliary Surgery, Zhongshan City People’s Hospital, Zhongshan 528499, China

    33 Department of Liver Transplantation Center, The Second Xiangya Hospital of Central South University, Changsha 410011, China

    34 Department of Hepatic Surgery and Liver Transplantation Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510062, China

    Keywords: Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

    ABSTRACT Mammalian target of rapamycin (mTOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant (LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival (RFS) in hepa- tocellular carcinoma (HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specific for the first 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefits for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese popula- tion data.

    Introduction

    Hepatocellular carcinoma (HCC) is a common malignancy with ever-growing morbidity and substantial mortality worldwide [1] . It is estimated that over half of all HCC cases and HCC-related deaths occur in China [2] . Liver transplantation (LT) is one of the most ef- fective life-saving treatments for HCC patients [3] . Compared with other surgical treatment options such as resection and ablation, LT takes its grips on conferring higher long-term survival benefits [4] .

    The immunosuppressive drugs ushered in a new dawn in the field of LT with properties of anti-rejection. However, a caveat of immunosuppression resides in the double-edged sword effects that not only reduces immunological rejection, but also adds to the risk of HCC recurrence and other complications compromising the long-term outcomes in liver recipients. Calcineurin inhibitors (CNIs), namely tacrolimus and cyclosporine, are widely used in clinical practice. Protumorigenic property is one of the primary issues of CNIs therapy. In LT rat model, both cyclosporine and tacrolimus have been shown to enhance liver tumor invasiveness and recurrence [ 5 , 6 ]. Clinically, the result is consistent with pre- clinical study and demonstrates that CNIs increase the risk of HCC recurrence after LT in a dose-dependent fashion [7] . Complica- tion such as renal insufficiency is also increased after LT, which is mainly due to the nephrotoxic effects of CNIs.

    An ideal acceptable immunosuppressant should be the one with minimal nephrotoxicity and no pro-tumorigenic effects. Recently, great attention has been bestowed to a new class of immunosup- pressive agent, mammalian target of rapamycin (mTOR) inhibitors. Sirolimus, the only approved mTOR inhibitor in China, is charac- terized with antitumorigenic effects and minimal nephrotoxicity. Mechanically,invivostudy shows that sirolimus significantly re- duces tumor growth and that this effect is mainly mediated by an- tiangiogenic effects [8] . In addition, sirolimus inhibits proliferation and migration phenotypes in HCC mice model via modulation of GP73 [9] . Another rationale is that mTOR pathway is vital in can- cer progressionperse, which has synergistic effects with antian- giogenic property to anti-hepatocarcinogenesis [10] .

    From clinical perspective, the phase 3 randomized controlled trial (RCT) named “SiLVER Study” with an 8-year follow-up period performed by Geissler et al. [11] (NCT00355862) demonstrated that sirolimus could provide a benefit of recurrence-free survival (RFS) at 3 years after transplantation, but not at the study end. Subgroup analysis showed that recipients within the Milan criteria signifi- cantly benefit in RFS during early post-LT period compared with recipients beyond the Milan criteria (no benefit across the whole period) [11] . In contrast, our previous study revealed that HCC pa- tients beyond the Milan criteria may benefit from sirolimus [12] . A recent meta-analysis included a total of 11 studies including 1 RCT testified the safety and effectiveness of sirolimus-based immuno- suppression in HCC patients following LT. The pooled results found that sirolimus-administrated recipients had lower recurrence com- pared with the control group [13] .

    As the differences exist in etiology, race, indications and proce- dures for LT between Western and Eastern models, evidence from Western studies may not be applicable in Eastern settings. Based on the experimental observations and clinical considerations, we designed a clinical trial in Chinese populations with the purpose to test whether sirolimus can improve RFS in LT patients. We pre- dict an improved RFS in LT patients treated with sirolimus.

    Methods/design

    Basic protocol overview

    This is an open-labeled, single-arm, prospective multicenter, real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in patients undergoing LT for HCC. We have named the trial the “LEAP-Sirolimus (LEAPS)”(ChiCTR210 0 042869) with a double meaning. Firstly, it refers to a combination of the sirolimus and name of our organization, namely Liver Elite Aspiration Network 9Plus. Secondly, “LEAPS”contains our expectation and prediction for giant leaps to be made in this trial. The study is planned for 4 years in total with a 2- year enrollment period and a 2-year follow-up ( Fig. 1 ). Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center- specific for the first 4-6 weeks. The following regimens integrate sirolimus into the regimens as a combination therapy with reduced CNI based on the condition of patients and centers.

    Fig. 1. Study scheme of LEAPS trial. LT: liver transplantation; HCC: hepatocellular carcinoma; HIV: human immunodeficiency virus; mTOR: mammalian target of rapamycin; MPA: mycophenolate mofetil; CNIs: calcineurin inhibitors.

    Notably, patients are not prohibited to use antitumor drugs in- cluding traditional chemotherapies, immunotherapies and target drugs, but detailed records of type, dosage and duration of med- ication are warranted.

    Inclusion criteria

    The trial enrolls all patients eligible for LT as listed by each of the participating centers. The specific inclusion criteria are as follows: age between 18 and 70 years, histologically proven HCC before early switch to sirolimus-based regimens, written informed consent given by the patient. Another inclusion criterion is accep- tance of both deceased liver donors and living liver donors. We only include patients beyond the Milan criteria at the time of LT but without macrovascular invasion (expect for branch of portal vein) and distant metastasis. One caveat is that the latter shall pre- vail when divergences emerge between pre-LT diagnosis and post- LT pathology.

    Exclusion criteria

    Patients meeting one of the following criteria are excluded: multiple-organ recipients, patients known to be hypersensitive to sirolimus or its derivates, hyperlipidemia refractory to optimal medical treatment (triglyceride ≥400 mg/dL or ≥4.6 mmol/L, to- tal cholesterol ≥300 mg/dL or ≥7.8 mmol/L), evidence of local or systemic infection, human immunodeficiency virus-positive pa- tients, platelets counts<35 × 109/L, white blood cell counts<1.5 × 109/L, urine routine: protein ++ or beyond, women who are pregnant, lactating or child-bearing potential not willing to take contraception, patients with history of non-HCC tumor within 5 years prior to inclusion (basal cell and squamous cell skin cancers that have been successfully treated are not included), patients with a psychological, familial, sociologic or geographic condition difficult to comply with study protocol or follow-up schedule, and under guardianship (e.g. individuals who are not able to freely give their informed consent).

    Withdrawal criteria

    Participants who meet the withdrawal criteria will be with- drawn from the study but not replaced. The withdrawal criteria for this study are as follows: participants who actively request to withdraw from the study (retract/revoke informed consent), lost to follow-up, taking medications prohibited for the trial, with a history of allergic reaction to sirolimus or its additives, pregnant, violating trial protocol, subjects censored at death, clinical cases when physicians in charge believe that continued participation in the study is not in the best interest of the patient considering any pathological event, clinical adverse event, or change in the sub- ject’s physical condition, and other reasons to be withdrawn from the study.

    Study objectives

    We predict that this sirolimus-based regimen will improve HCC-free survival in LT population. The primary endpoint of this study is the occurrence of metastasis and/or recurrence after LT procedure. Secondary endpoints include tumor-related death, inci- dence of allograft rejection, graft loss and alterations in renal func- tion.

    Treatment scheme

    Patients are treated with center-specific immunosuppressive protocol for the first 4-6 weeks, excluding use of any mTOR- inhibitor medications. The initial immunosuppressant regimens in- clude CNIs ± mycophenolic acid (MPA) ± glucocorticoid immuno- suppressant ± IL-2 inhibitor (basiliximab) regimen. Tacrolimus is preferred in CNIs drugs. MPA drugs can be Cellcept (MMF) or My- fortic (EC-MPS). Four to ten ng/mL for sirolimus and 50% reduction in CNIs are recommended but not strictly restricted. The choice of regimen and dose of drugs should be based on the condition of patients and centers. Our only requirement is comprising sirolimus conversion regimen including the use of sirolimus starting between day 29 and day 42 after LT and a simultaneous reduction in CNIs.

    Follow-up and documentation

    All patients enrolled in the study will be followed up at least 7 times in 2 years. Follow-up examinations will be done on second and third month, then every 3 months to the end of first year and every 6 months to the end of second year.

    The management of the data in the study is performed using the Electronic Data Capture (EDC) system. Trial data will be col- lected through the electronic case record form (eCRF). Regular doc- umentations include evaluation of symptoms and signs, monitor- ing the trough concentrations of CNIs and sirolimus, patient recur- rence/metastasis information and patient survival, changes in re- nal function, concomitant medication (e.g., type, dosage and du- ration) and adverse event information. Lost-to-follow-up is de- fined as missing two consecutive follow-up visits. If the last con- tact is prior to the diagnosis of a recurrence/metastasis event, recurrence/metastasis-free survival time is censored using the date of the last contact. If patient can be re-contacted, the status should be reset to alive. Notably, recurrence/metastasis-free survival time and corresponding censoring status will remain. If definite date of a patient’s death is documented, the status will be "dead".

    Endpoint definition

    The definition of HCC RFS is the time interval between the first date of LT and the date of HCC recurrence/metastasis or death; censored for RFS will be made for patients alive or recurrence-free at the time of their last contact. HCC recur- rence/metastasis is defined as either histologically confirmed tu- mor recurrence/metastasis, or unequivocal evidence according to the Barcelona Criteria (Barcelona-20 0 0 EASL Conference). Date of recurrence is defined as the first day of tumor suspicion. Clinical evidence for HCC recurrence includes symptoms and signs (e.g., pruritis and ascites), laboratory examination [e.g., alpha-fetoprotein (AFP) and PIVKA-II], liver image by computerized tomography or magnetic resonance imaging, as well as diagnostic action of Barcelona Criteria. Recurrence of HCC can therefore be evaluated through the whole follow-up period besides the protocol required visits.

    Trial organization

    The study is an investigator-initiated trial. Preliminary inves- tigator meetings to plan the details of the trial protocol were organized by Shulan (Hangzhou) Hospital and Hangzhou First People’s Hospital. Services for site monitoring, data management and arranging regulatory affairs are provided by experts familiar with the trial in Shulan (Hangzhou) Hospital and Hangzhou First People’s Hospital. Statistical research is performed within Shulan (Hangzhou) Hospital, Hangzhou First People’s Hospital and China Liver Transplant Registry.

    Participating centers

    Major liver transplant centers from different provinces are par- ticipating this clinical trial. In total, 33 sites covering most parts of China up to 19 provinces have committed to participate the study.

    Drug supply

    One mg sirolimus (Rapamune) blisters produced by Pfizer Ire- land Pharmaceuticals (Little Connell, Newbridge, Co. Kildare, Ire- land) is used as study medication in participating centers.

    Quality control and on-site monitoring

    Quality control is performed across whole process of the study including screening and determination of eligibility of research centers, laboratory and researchers to fully meet requirements of the national law “Quality Management Practice for Medical Device Clinical Trials” in China. Recruitment and follow-up of patients, regular monitoring of safety and endpoint data are performed ac- cording to good clinical practice (GCP) guidelines. Data manage- ment is performed by each center and documentations from clini- cal trials are maintained and managed in accordance with the GCP requirements.

    Ethics and safety

    Protocol version 1 has been reviewed and approved by the re- sponsible Institutional Review Board/Institutional Ethics Commit- tee (IRB/IEC) for all of centers. The study protocol complies with theDeclarationofHelsinkiand principles of the GCP guidelines. Written informed consent is obtained from all participants at en- rollment. Each patient is fully informed about the procedure of the trial and liable reasonable risk by an experienced physician famil- iar with the study. The safety and all potential side effects for the patients are monitored at least once a year by IRB/IEC. Qualified personnel from all sites should also attend meeting regularly to review safety data, including adverse events and serious adverse events. Any information deemed to potentially affect the safety of the trial should be reported to IRB/IEC in time.

    Statistical analysis

    A one-sided, one-sample log-rank test calculated from a sample of 397 subjects achieves 90.1% power at a 0.025 significance level to detect a median survival time of 1.20-fold in the new group when the median survival time of the historic control group is 1.00. Subjects are accrued for 2.0 years. Follow-up that continues for 2 years after the last subject is added. The probability of a sub- ject experiencing an event during the study is 0.8132. The expected number of events during the study is 323. It is assumed that the survival time distributions of both groups are approximated rea- sonably well by the Weibull distribution with a shape parameter of 1.00.

    Demographic and clinical characteristics of participants are summarized using standard descriptive statistics. Time-to-event end points including RFS, overall survival (OS) and tumor-related death are assessed at the end of the study estimated by the Kaplan-Meier method. As part of the secondary analysis, we mainly focus on the alterations in renal function as its potential renal protective effect. Further stratified analyses are performed on the stratification of adjuvant therapy. Safety parameters for inci- dence of adverse events are analyzed based on the safety analysis set which is defined as subjects who receive at least one dose of study drug. All continuous variables are compared by Student’st- test or rank-sum test and rate is compared by Chi-square test.

    Discussion

    There are two substantial issues in patients undergoing LT pro- cedure for HCC: graft rejection and tumor recurrence. Recent stud- ies have shown that sirolimus bears a potential antitumorigenic ef- fects [ 6 , 9 , 10 ]. The SiLVER study is the first RCT trial which eval- uates HCC recurrence in LT recipients [11] . Results by the confir- matory analysis of the SiLVER-trial in 2016 have drawn three im- portant conclusions. Firstly, sirolimus conversion does not improve long-term RFS beyond 5 years in LT recipients with HCC. Secondly, younger (age ≤60 years), low-risk (within the Milan criteria) re- cipients and patients with sirolimus monotherapy also benefited from sirolimus treatment. Thirdly, no contraindicative overall dis- advantage regarding serious adverse events of sirolimus therapy became apparent during the trial. The trial lays the foundation for applying sirolimus-based immunosuppressive regimen to LT pa- tients with HCC and provides a reasonable clinical rationale for our study. Although sirolimus treatment provides a survival advantage up to 5 years after transplantation, it seems ambiguous for the an- titumor effect as it’s diminishing RFS benefits. More recently, the SiLVER-trial published its data with exploratory approach revealing a clearer antitumor effect [14] . The analysis included data from 508 patients with a follow-up period of 72.4 months on average. Mul- tivariate analysis showed an independent benefit of sirolimus use for ≥3 months for OS. Subgroup analysis demonstrated that the patients deriving the maximum benefit reside in those with AFP ≥10 ng/mL and having used sirolimus for ≥3 months with regard to OS, disease-free survival, and HCC recurrence. Higher tumor ac- tivity in LT patients with AFP evidence is advocated for mTOR in- hibitor use.

    Here, we put forward three key issues to consider when design- ing this trial. The first consideration is that our study population only includes LT patients with HCC (beyond the Milan criteria) and without macrovascular invasion (expect for branch of portal vein) and distant metastasis. This trial is a continuation of our previous work that revealed recipients exceeding, rather than meeting, the Milan criteria may benefit from sirolimus [12] . Among recipients beyond the Milan criteria, our unpublished data suggest a signif- icant survival benefit in branch invasion of portal vein compared with major portal vein invasion. And we have observed compara- ble prognosis between the branch invasion of portal vein group and without macrovascular invasion group. Our reasoning is that particular patients beyond the Milan criteria and with branch in- vasion of portal vein may benefit most from sirolimus conversion regimen, similar to the finding that higher tumor activity in LT may benefit from sirolimus use as declared in SiLVER study. Ad- ditionally, choosing RFS as our primary endpoint is another critical point. According to the published data from SiLVER study, encour- aging results demonstrate a clear antitumor effect particularly in patients with AFP ≥10 ng/mL and having used sirolimus for ≥3 months. In our study, we assert a similar benefit of sirolimus in prognosis (e.g., lower recurrence rate, later tumor redevelopment, longer survival time after recurrence). Thus, single-arm trial using sirolimus conversion is preferred after intense debate for ethical considerations. Final issue to consider is that our study is aimed to provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data. A limita- tion of the trial is the intrinsic disadvantage of single-arm study. Without simultaneous control, it may undermine the credibility of research as the survival rate of recipients undergoing LT procedure may be higher than the counterpart in previous studies regard- ing the development of antitumor drugs, surgery technology and medical conditions. Essentially, we prospectively assess the clinical value of sirolimus in a real-world setting without prohibiting ad- ditional therapy (e.g., immunotherapies and target drugs) to bet- ter reflect the actual clinical benefits for LT recipients beyond the Milan criteria. We expect to provide multiple immunosuppressant regimens for clinicians and patients in the clinical scenario.

    The LEAPS study is the first open-labeled, single-arm, prospec- tive multicenter, real-world trial based on Chinese population that primarily evaluates HCC recurrence in LT recipients beyond the Milan criteria. We predict that sirolimus conversion regimen will provide survival benefits for patients particular in the key indica- tor “RFS” as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator “OS”.

    Acknowledgments

    The authors would like to dedicate this article to the memory of the late Yun-Jin Zang, the esteemed pioneer in the field of liver transplantation for his inspiration and assistance in initiating this clinical trial.

    CRediT authorship contribution statement

    Ren-YiSu:Conceptualization, Visualization, Writing - original draft.Sun-BinLing:Conceptualization, Writing - review & editing.Qiao-NanShan:Conceptualization, Project administration, Data curation, Writing - review & editing.Xu-YongWei:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.RuiWang: Methodology, Formal analysis, Software, Writing - review & editing.Chang-KuJia:Conceptualization, Project ad- ministration, Data curation, Writing - review & editing.LiZhuang:Conceptualization, Project administration, Data curation, Writing - review & editing.TianShen:Conceptualization, Project adminis- tration, Data curation, Writing - review & editing.Li-MinDing:Conceptualization, Project administration, Data curation, Writing - review & editing.Zhi-DanXu:Conceptualization, Project adminis- tration, Data curation, Writing - review & editing.Lai-BangLuo:Conceptualization, Project administration, Data curation, Writing - review & editing.Li-BoSun:Conceptualization, Project administra- tion, Data curation, Writing - review & editing, Writing - review & editing.Guang-MingLi:Conceptualization, Project administration, Data curation, Writing - review & editing.Tai-ShiFang:Conceptu- alization, Project administration, Data curation, Writing - review & editing.NanJiang:Conceptualization, Project administration, Data curation, Writing - review & editing.KunZhang:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.Zhao-JieSu:Conceptualization, Project administration, Data curation, Writing - review & editing.Zhi-HaiPeng:Conceptual- ization, Project administration, Data curation, Writing - review & editing.RenLang:Conceptualization, Project administration, Data curation, Writing - review & editing.TaoJiang:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.QiangHe:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Lin-SenYe:Conceptualization, Project administration, Data curation, Writing - review & editing.YangYang:Conceptualization, Project administration, Data cura- tion, Writing - review & editing.Yu-TingHe:Conceptualization, Project administration, Data curation, Writing - review & editing.Wen-ZhiGuo:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Liu-GenLan:Conceptualization, Project administration, Data curation, Writing - review & editing.Xu-YongSun:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.DongChen:Conceptualization, Project administration, Data curation, Writing - review & editing.Zhi-ShuiChen:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Da-WeiZhou:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.Shao-JunYe:Conceptualization, Project administration, Data curation, Writing - review & editing.Qi-FaYe:Conceptualization, Project administration, Data curation, Writing - review & edit- ing.MinTian:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Jian-HuaShi:Conceptualization, Project administration, Data curation, Writing - review & editing.BoWang:Conceptualization, Project administration, Data curation, Writing - review & editing.JiangLiu:Conceptualization, Project administration, Data curation, Writing - review & editing.QianLu:Conceptualization, Project administration, Data curation, Writing - review & editing.WeiRao:Conceptualization, Project administra- tion, Data curation, Writing - review & editing.Jin-ZhenCai:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.TaoLv:Conceptualization, Project administration, Data curation, Writing - review & editing.Jia-YinYang:Concep- tualization, Project administration, Data curation, Writing - review & editing.Pu-SenWang:Conceptualization, Project administration, Data curation, Writing - review & editing.LinZhong:Conceptu- alization, Project administration, Data curation, Writing - review & editing.Jing-ShengMa:Conceptualization, Project administra- tion, Data curation, Writing - review & editing.Qi-GenLi:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.Sheng-DongWu:Conceptualization, Project ad- ministration, Data curation, Writing - review & editing.Chang-JiangLu:Conceptualization, Project administration, Data curation, Writing - review & editing.Cai-DeLu:Conceptualization, Project administration, Data curation, Writing - review & editing.Dong-HuaZhang:Conceptualization, Project administration, Data cura- tion, Writing - review & editing.XuanWang:Conceptualization, Project administration, Data curation, Writing - review & editing.Zi-QiangLi:Conceptualization, Project administration, Data cura- tion, Writing - review & editing.Mu-JianTeng:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.Jun-JieLi:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Wen-TaoJiang:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.Jian-HuaLi:Conceptualization, Project administration, Data curation, Writing - review & editing.Quan-BaoZhang:Concep- tualization, Project administration, Data curation, Writing - review & editing.Ning-QiZhu:Conceptualization, Project administration, Data curation, Writing - review & editing.Zheng-XinWang:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.KangHe:Conceptualization, Project administration, Data curation, Writing - review & editing.QiangXia:Conceptu- alization, Project administration, Data curation, Writing - review & editing.Shao-HuaSong:Conceptualization, Project administra- tion, Data curation, Writing - review & editing.Zhi-RenFu:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.WeiQiu:Conceptualization, Project administration, Data curation, Writing - review & editing.Guo-YueLv:Conceptu- alization, Project administration, Data curation, Writing - review & editing.Rui-PengSong:Conceptualization, Project administration, Data curation, Writing - review & editing.Ji-ZhouWang:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.ZhengWang:Conceptualization, Project adminis- tration, Data curation, Writing - review & editing.JianZhou:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.GangChen:Conceptualization, Project administra- tion, Data curation, Writing - review & editing.Ying-PengZhao:Conceptualization, Project administration, Data curation, Writing - review & editing.LiLi:Conceptualization, Project administration, Data curation, Writing - review & editing.Ze-MinHu:Conceptu- alization, Project administration, Data curation, Writing - review & editing.Qi-JieLuo:Conceptualization, Project administration, Data curation, Writing - review & editing.Zhong-ZhouSi:Conceptu- alization, Project administration, Data curation, Writing - review & editing.BinXie:Conceptualization, Project administration, Data curation, Writing - review & editing.Xiao-ShunHe:Conceptual- ization, Project administration, Data curation, Writing - review & editing.Zhi-YongGuo:Conceptualization, Project administration, Data curation, Writing - review & editing.Shu-SenZheng:Con- ceptualization, Supervision, Writing - review & editing.XiaoXu:Conceptualization, Supervision, Funding acquisition, Writing - re- view & editing.

    Funding

    This study was supported by grants from the National S&T Ma- jor Project (2017ZX10203205), Key Program, National Natural Sci- ence Foundation of China ( 81930016 ) and Zhejiang Provincial Nat- ural Science Foundation of China (LY21H160026).

    Ethical approval

    This study was reviewed and approved by the Institutional Re- view Board/Institutional Ethics Committee in each center.

    Competing interest

    No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the sub- ject of this article.

    videos熟女内射| 国产成人精品在线电影| 性色avwww在线观看| 日韩伦理黄色片| 久久久久久久久久人人人人人人| 青春草国产在线视频| 看免费av毛片| 日韩人妻精品一区2区三区| 久久久精品免费免费高清| 中文乱码字字幕精品一区二区三区| 大片电影免费在线观看免费| 久久久亚洲精品成人影院| 国产精品.久久久| 晚上一个人看的免费电影| 老司机影院成人| 97在线视频观看| freevideosex欧美| av视频免费观看在线观看| 黄网站色视频无遮挡免费观看| 亚洲 欧美一区二区三区| 看非洲黑人一级黄片| 免费观看在线日韩| 国产在线一区二区三区精| 99久国产av精品国产电影| 搡老乐熟女国产| 亚洲天堂av无毛| 亚洲欧美一区二区三区黑人 | 一区二区三区乱码不卡18| 日本wwww免费看| 免费观看在线日韩| 女性生殖器流出的白浆| 人人妻人人澡人人爽人人夜夜| 精品99又大又爽又粗少妇毛片| 男女高潮啪啪啪动态图| 亚洲精品aⅴ在线观看| 欧美97在线视频| av女优亚洲男人天堂| 一边亲一边摸免费视频| 国产免费一级a男人的天堂| 中文字幕免费在线视频6| 精品久久久精品久久久| 各种免费的搞黄视频| 精品熟女少妇av免费看| 一级片'在线观看视频| 最近中文字幕2019免费版| 欧美97在线视频| 少妇人妻精品综合一区二区| 国产成人av激情在线播放| 亚洲美女黄色视频免费看| 91精品三级在线观看| 国产一级毛片在线| 日本爱情动作片www.在线观看| 国产欧美亚洲国产| 不卡视频在线观看欧美| 亚洲三级黄色毛片| 中文字幕制服av| 极品人妻少妇av视频| 日韩熟女老妇一区二区性免费视频| 亚洲精品一区蜜桃| 国产乱来视频区| 少妇 在线观看| 热re99久久精品国产66热6| 亚洲精品国产av蜜桃| 九九爱精品视频在线观看| 亚洲精品av麻豆狂野| 免费观看av网站的网址| 日韩成人伦理影院| 欧美成人午夜免费资源| 欧美精品亚洲一区二区| 男女国产视频网站| 99热国产这里只有精品6| 精品国产露脸久久av麻豆| 国产淫语在线视频| 亚洲av在线观看美女高潮| 人妻系列 视频| 国产在视频线精品| 国产成人av激情在线播放| 多毛熟女@视频| 一本—道久久a久久精品蜜桃钙片| 亚洲精品,欧美精品| 国产片内射在线| 26uuu在线亚洲综合色| a级毛片在线看网站| 边亲边吃奶的免费视频| 国产男女超爽视频在线观看| 赤兔流量卡办理| 18禁动态无遮挡网站| 老司机亚洲免费影院| 免费观看性生交大片5| 精品久久久久久电影网| 国产成人精品无人区| 90打野战视频偷拍视频| 日本欧美视频一区| 女的被弄到高潮叫床怎么办| 亚洲婷婷狠狠爱综合网| 色吧在线观看| 欧美亚洲 丝袜 人妻 在线| 欧美人与善性xxx| 欧美亚洲日本最大视频资源| 99久久综合免费| 精品一区二区免费观看| 天堂中文最新版在线下载| 午夜视频国产福利| 国产无遮挡羞羞视频在线观看| 老司机亚洲免费影院| 人人澡人人妻人| 国产麻豆69| 亚洲成人av在线免费| 成人免费观看视频高清| 欧美精品高潮呻吟av久久| 成人综合一区亚洲| 一级黄片播放器| 国产成人免费无遮挡视频| 大片电影免费在线观看免费| av福利片在线| 亚洲精品视频女| 五月开心婷婷网| 午夜免费观看性视频| 亚洲国产毛片av蜜桃av| 飞空精品影院首页| 亚洲精品成人av观看孕妇| 一本久久精品| 男女高潮啪啪啪动态图| 亚洲内射少妇av| 免费播放大片免费观看视频在线观看| 男女下面插进去视频免费观看 | 日韩制服骚丝袜av| av在线观看视频网站免费| av网站免费在线观看视频| 国产欧美亚洲国产| 亚洲国产看品久久| 男女午夜视频在线观看 | 久久久国产精品麻豆| 久久久久久久久久成人| 国产精品久久久av美女十八| 涩涩av久久男人的天堂| 婷婷成人精品国产| 秋霞在线观看毛片| 少妇 在线观看| 美女国产高潮福利片在线看| 丰满少妇做爰视频| 精品少妇内射三级| 搡老乐熟女国产| 国产精品秋霞免费鲁丝片| 亚洲av欧美aⅴ国产| 欧美日韩一区二区视频在线观看视频在线| 99re6热这里在线精品视频| 亚洲精品一二三| 巨乳人妻的诱惑在线观看| 飞空精品影院首页| 亚洲精品日本国产第一区| 少妇猛男粗大的猛烈进出视频| 亚洲精品色激情综合| 日本wwww免费看| 最黄视频免费看| 亚洲色图 男人天堂 中文字幕 | 男女午夜视频在线观看 | 男女边摸边吃奶| 99视频精品全部免费 在线| 看免费成人av毛片| 亚洲成人av在线免费| 熟女电影av网| 欧美日韩一区二区视频在线观看视频在线| 成人亚洲欧美一区二区av| 妹子高潮喷水视频| 晚上一个人看的免费电影| 亚洲色图 男人天堂 中文字幕 | 中国美白少妇内射xxxbb| 国产日韩欧美亚洲二区| 亚洲高清免费不卡视频| 久久久久人妻精品一区果冻| 亚洲av欧美aⅴ国产| 免费高清在线观看日韩| 亚洲av电影在线进入| 大陆偷拍与自拍| 99国产精品免费福利视频| 亚洲成av片中文字幕在线观看 | 精品国产国语对白av| 亚洲高清免费不卡视频| av卡一久久| 中国国产av一级| 青春草亚洲视频在线观看| 久久久久人妻精品一区果冻| 男女国产视频网站| 欧美国产精品一级二级三级| 中国三级夫妇交换| 亚洲伊人久久精品综合| 国产欧美另类精品又又久久亚洲欧美| 免费久久久久久久精品成人欧美视频 | 亚洲国产欧美日韩在线播放| 国产欧美日韩一区二区三区在线| 久久人人97超碰香蕉20202| 国产乱人偷精品视频| 亚洲欧美色中文字幕在线| 亚洲丝袜综合中文字幕| 欧美人与善性xxx| 亚洲成人av在线免费| 国产成人91sexporn| 五月玫瑰六月丁香| 少妇人妻 视频| 制服诱惑二区| 少妇人妻久久综合中文| 2018国产大陆天天弄谢| 有码 亚洲区| 制服人妻中文乱码| 久久精品久久精品一区二区三区| videossex国产| 一本大道久久a久久精品| 国产精品久久久久成人av| 欧美xxxx性猛交bbbb| 欧美日韩亚洲高清精品| 亚洲国产毛片av蜜桃av| 亚洲成av片中文字幕在线观看 | 少妇 在线观看| 青春草国产在线视频| 涩涩av久久男人的天堂| 国产亚洲精品第一综合不卡 | 久久99精品国语久久久| 18在线观看网站| 中文欧美无线码| 中国三级夫妇交换| 国产男人的电影天堂91| 多毛熟女@视频| 久久热在线av| 日本爱情动作片www.在线观看| 最后的刺客免费高清国语| 九色亚洲精品在线播放| 建设人人有责人人尽责人人享有的| 国产69精品久久久久777片| 国产深夜福利视频在线观看| 国产亚洲精品第一综合不卡 | 两性夫妻黄色片 | 女人精品久久久久毛片| 亚洲精品乱久久久久久| 久久午夜综合久久蜜桃| 高清不卡的av网站| 久久久久精品性色| 纯流量卡能插随身wifi吗| 在线观看一区二区三区激情| 巨乳人妻的诱惑在线观看| 欧美激情国产日韩精品一区| 欧美日本中文国产一区发布| 大香蕉久久成人网| 国产一区二区在线观看av| 啦啦啦在线观看免费高清www| av一本久久久久| 91精品国产国语对白视频| 国产片特级美女逼逼视频| 欧美丝袜亚洲另类| 国产亚洲av片在线观看秒播厂| 18禁国产床啪视频网站| 国产精品一区二区在线观看99| 最近最新中文字幕大全免费视频 | 日本-黄色视频高清免费观看| 亚洲精品,欧美精品| 亚洲av成人精品一二三区| 丰满乱子伦码专区| 久久午夜福利片| 九色亚洲精品在线播放| 久久精品国产亚洲av天美| 少妇精品久久久久久久| 激情五月婷婷亚洲| 嫩草影院入口| a 毛片基地| 亚洲国产精品国产精品| 久久这里有精品视频免费| 国产在线视频一区二区| 成人毛片a级毛片在线播放| 国产国语露脸激情在线看| 自拍欧美九色日韩亚洲蝌蚪91| 少妇人妻久久综合中文| 人体艺术视频欧美日本| 国产精品99久久99久久久不卡 | 少妇精品久久久久久久| 中文字幕免费在线视频6| 免费黄网站久久成人精品| 久久精品熟女亚洲av麻豆精品| 国产伦理片在线播放av一区| 亚洲成色77777| 交换朋友夫妻互换小说| 制服诱惑二区| 亚洲综合色网址| 高清不卡的av网站| 在线 av 中文字幕| 亚洲精品国产av蜜桃| 日韩电影二区| 久久久久国产网址| 高清黄色对白视频在线免费看| 婷婷色麻豆天堂久久| 国产精品秋霞免费鲁丝片| 亚洲av福利一区| 校园人妻丝袜中文字幕| 热99国产精品久久久久久7| 国产精品国产三级国产专区5o| 久久久久久久大尺度免费视频| 久久精品国产鲁丝片午夜精品| 亚洲成人av在线免费| 欧美日韩精品成人综合77777| 亚洲av.av天堂| 丰满迷人的少妇在线观看| 人人澡人人妻人| www日本在线高清视频| 啦啦啦啦在线视频资源| 国产成人精品一,二区| 日韩熟女老妇一区二区性免费视频| 亚洲av日韩在线播放| 日韩伦理黄色片| 久久久精品94久久精品| 日韩成人av中文字幕在线观看| 精品国产国语对白av| 51国产日韩欧美| 欧美成人午夜免费资源| 亚洲精品久久成人aⅴ小说| 欧美激情国产日韩精品一区| 日本免费在线观看一区| 国产精品国产三级专区第一集| 久久久久久伊人网av| 亚洲欧洲精品一区二区精品久久久 | 天天操日日干夜夜撸| 欧美精品人与动牲交sv欧美| 成人黄色视频免费在线看| 日韩大片免费观看网站| 中文字幕最新亚洲高清| 一区二区三区四区激情视频| 9热在线视频观看99| 热re99久久精品国产66热6| av在线老鸭窝| 18+在线观看网站| 久久国产精品大桥未久av| av在线观看视频网站免费| 国产激情久久老熟女| 99久久综合免费| 在线亚洲精品国产二区图片欧美| 久久久欧美国产精品| 大香蕉久久成人网| www.熟女人妻精品国产 | 捣出白浆h1v1| 亚洲精品乱码久久久久久按摩| 亚洲av福利一区| 国产精品嫩草影院av在线观看| 一个人免费看片子| 中文字幕另类日韩欧美亚洲嫩草| 色吧在线观看| 国精品久久久久久国模美| 如何舔出高潮| 久久鲁丝午夜福利片| 男人操女人黄网站| 久久热在线av| 少妇人妻精品综合一区二区| 两个人免费观看高清视频| 91午夜精品亚洲一区二区三区| 男女边吃奶边做爰视频| 最近的中文字幕免费完整| 久热这里只有精品99| 国产福利在线免费观看视频| 亚洲av.av天堂| 一本大道久久a久久精品| 老女人水多毛片| 国产成人精品久久久久久| 国产男人的电影天堂91| 欧美日韩av久久| 在线观看免费视频网站a站| 伊人亚洲综合成人网| 男女边吃奶边做爰视频| 少妇人妻精品综合一区二区| 少妇被粗大的猛进出69影院 | 国产国语露脸激情在线看| 男男h啪啪无遮挡| 男女午夜视频在线观看 | 精品酒店卫生间| 午夜av观看不卡| 免费大片18禁| 日韩一区二区三区影片| 18禁国产床啪视频网站| 免费高清在线观看视频在线观看| 国产日韩一区二区三区精品不卡| 少妇熟女欧美另类| 亚洲欧美成人精品一区二区| 1024视频免费在线观看| 久久影院123| 丝袜在线中文字幕| 久久久久精品人妻al黑| 国产一区二区三区av在线| 免费观看性生交大片5| 内地一区二区视频在线| 女人久久www免费人成看片| 国产极品粉嫩免费观看在线| 91精品伊人久久大香线蕉| 新久久久久国产一级毛片| 免费女性裸体啪啪无遮挡网站| 十分钟在线观看高清视频www| 在线 av 中文字幕| 午夜免费观看性视频| 欧美亚洲 丝袜 人妻 在线| 综合色丁香网| 在线亚洲精品国产二区图片欧美| 五月开心婷婷网| 桃花免费在线播放| 热99国产精品久久久久久7| 午夜福利乱码中文字幕| 欧美精品一区二区大全| 久久久国产一区二区| 韩国av在线不卡| 日本黄色日本黄色录像| 亚洲国产av影院在线观看| 亚洲av免费高清在线观看| 考比视频在线观看| 黄片无遮挡物在线观看| 国产免费视频播放在线视频| 老熟女久久久| 精品熟女少妇av免费看| 久久久久视频综合| 中文乱码字字幕精品一区二区三区| 免费看不卡的av| 欧美日韩成人在线一区二区| 校园人妻丝袜中文字幕| 三上悠亚av全集在线观看| 色网站视频免费| 少妇的逼好多水| 久久久久久久大尺度免费视频| 精品国产露脸久久av麻豆| 亚洲av成人精品一二三区| 大片免费播放器 马上看| av线在线观看网站| 男女免费视频国产| 国产片内射在线| 精品一区二区三区视频在线| 两个人免费观看高清视频| 久久99蜜桃精品久久| 亚洲色图综合在线观看| 日韩制服丝袜自拍偷拍| 亚洲欧美一区二区三区黑人 | 欧美精品人与动牲交sv欧美| 男女高潮啪啪啪动态图| 少妇人妻精品综合一区二区| 久久久久国产网址| 国产欧美另类精品又又久久亚洲欧美| 亚洲欧美中文字幕日韩二区| 免费看光身美女| 免费不卡的大黄色大毛片视频在线观看| 国产精品久久久久久精品电影小说| 赤兔流量卡办理| 日韩中字成人| 色婷婷久久久亚洲欧美| 免费在线观看完整版高清| 菩萨蛮人人尽说江南好唐韦庄| 男人爽女人下面视频在线观看| 久久精品熟女亚洲av麻豆精品| 只有这里有精品99| 日韩欧美精品免费久久| 精品人妻在线不人妻| av在线观看视频网站免费| av天堂久久9| 自线自在国产av| 丝袜人妻中文字幕| 国产精品女同一区二区软件| 日日啪夜夜爽| 最近最新中文字幕大全免费视频 | 中文精品一卡2卡3卡4更新| 免费黄色在线免费观看| 人妻一区二区av| 成人国产av品久久久| 99热网站在线观看| 国产片特级美女逼逼视频| 久久这里有精品视频免费| 国产国语露脸激情在线看| 老司机亚洲免费影院| 久久鲁丝午夜福利片| 亚洲综合色网址| 三上悠亚av全集在线观看| 久久热在线av| a级毛片黄视频| 国产成人精品福利久久| 日本猛色少妇xxxxx猛交久久| 一边摸一边做爽爽视频免费| 女性生殖器流出的白浆| 成人国产av品久久久| 亚洲美女视频黄频| 97人妻天天添夜夜摸| 国产一区二区激情短视频 | 99国产精品免费福利视频| 少妇被粗大猛烈的视频| 人妻少妇偷人精品九色| 国产免费现黄频在线看| 久久ye,这里只有精品| 久久久a久久爽久久v久久| 亚洲av中文av极速乱| 丝袜美足系列| 亚洲国产看品久久| 人人妻人人澡人人看| 亚洲人与动物交配视频| 美女脱内裤让男人舔精品视频| 久久热在线av| 久久精品熟女亚洲av麻豆精品| 国产国语露脸激情在线看| 少妇人妻精品综合一区二区| 全区人妻精品视频| 亚洲精品久久午夜乱码| 在线观看人妻少妇| 五月开心婷婷网| 亚洲内射少妇av| 另类精品久久| 中文天堂在线官网| 亚洲色图综合在线观看| 在线亚洲精品国产二区图片欧美| 中文字幕另类日韩欧美亚洲嫩草| 国产视频首页在线观看| 妹子高潮喷水视频| 亚洲中文av在线| www.熟女人妻精品国产 | 亚洲精品,欧美精品| 美国免费a级毛片| 亚洲在久久综合| 97在线视频观看| 国产日韩欧美亚洲二区| av.在线天堂| 日本爱情动作片www.在线观看| 久久婷婷青草| 亚洲美女视频黄频| 超碰97精品在线观看| 欧美精品人与动牲交sv欧美| 亚洲婷婷狠狠爱综合网| 亚洲在久久综合| 国产亚洲最大av| 日韩视频在线欧美| www.色视频.com| 在线亚洲精品国产二区图片欧美| 精品福利永久在线观看| 性色avwww在线观看| 国产伦理片在线播放av一区| 久久久国产一区二区| 精品亚洲成a人片在线观看| 美女主播在线视频| 欧美丝袜亚洲另类| 国产福利在线免费观看视频| 美国免费a级毛片| 久久女婷五月综合色啪小说| av卡一久久| 亚洲精品美女久久av网站| 免费av中文字幕在线| 亚洲第一av免费看| 日韩制服骚丝袜av| 久久久久久久大尺度免费视频| 亚洲av欧美aⅴ国产| 又黄又粗又硬又大视频| 五月开心婷婷网| 国产片内射在线| 国产日韩欧美在线精品| 亚洲综合色惰| 晚上一个人看的免费电影| 日韩人妻精品一区2区三区| 午夜福利影视在线免费观看| av有码第一页| 免费观看性生交大片5| 亚洲人成网站在线观看播放| 亚洲综合色网址| 极品少妇高潮喷水抽搐| 成人黄色视频免费在线看| 欧美国产精品va在线观看不卡| h视频一区二区三区| 成人毛片a级毛片在线播放| 中文字幕最新亚洲高清| 性色av一级| 久久亚洲国产成人精品v| 人人妻人人澡人人爽人人夜夜| 久久这里只有精品19| 美女内射精品一级片tv| 精品酒店卫生间| 视频中文字幕在线观看| 亚洲欧美成人精品一区二区| 丰满乱子伦码专区| 成年动漫av网址| 又粗又硬又长又爽又黄的视频| 少妇精品久久久久久久| 免费不卡的大黄色大毛片视频在线观看| 亚洲国产精品国产精品| 亚洲综合色惰| 极品少妇高潮喷水抽搐| 菩萨蛮人人尽说江南好唐韦庄| 狠狠精品人妻久久久久久综合| 波多野结衣一区麻豆| 婷婷色av中文字幕| 国产熟女午夜一区二区三区| 国产无遮挡羞羞视频在线观看| 成人手机av| 超碰97精品在线观看| 波多野结衣一区麻豆| 999精品在线视频| 亚洲精品乱码久久久久久按摩| 亚洲国产精品成人久久小说| 男女下面插进去视频免费观看 | 国产在线免费精品| 在线观看免费高清a一片| 女人久久www免费人成看片| 国产精品久久久久久av不卡| videosex国产| av国产久精品久网站免费入址| 人人妻人人澡人人爽人人夜夜| 午夜福利视频精品| 婷婷色麻豆天堂久久| 亚洲欧美一区二区三区黑人 | 精品一区二区免费观看| 久久精品国产亚洲av天美| 最新中文字幕久久久久| 黑人巨大精品欧美一区二区蜜桃 | 美女视频免费永久观看网站| 午夜av观看不卡| 另类精品久久| 中文字幕人妻熟女乱码| 久久久久久人妻| 一区二区av电影网| 99久久人妻综合| 日本vs欧美在线观看视频| 亚洲欧美色中文字幕在线| 午夜激情久久久久久久|